var data={"title":"Prednisone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prednisone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6835?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">see &quot;Prednisone: Drug information&quot;</a> and <a href=\"topic.htm?path=prednisone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prednisone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213098\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Deltasone;</li>\n      <li>PredniSONE Intensol;</li>\n      <li>Rayos</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213099\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Prednisone;</li>\n      <li>JAA-Prednisone;</li>\n      <li>Teva-Prednisone;</li>\n      <li>Winpred</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055060\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Systemic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055053\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">see &quot;Prednisone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> All pediatric dosing based on immediate release products. Dose depends upon condition being treated and response of patient; dosage for infants and children should be based on disease severity and patient response rather than by rigid adherence to dosage guidelines by age, weight, or body surface area. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing; anti-inflammatory or immunosuppressive:</b> Infants, Children, and Adolescents: Oral 0.05 to 2 mg/kg/day divided every 6 to 24 hours (Bertsias 2012; Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, acute exacerbation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">NAEPP 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Emergency care or hospital doses:</i> 1 to 2 mg/kg/day in 2 divided doses; maximum daily dose: 60 mg/<b>day</b>; continue until peak expiratory flow is 70% of predicted or personal best</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Short-course &ldquo;burst&rdquo; (Outpatient):</i> 1 to 2 mg/kg/day in divided doses 1 to 2 times daily for 3 to 10 days; maximum daily dose: 60 mg/<b>day</b>; <b>Note:</b> Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Emergency care or hospital doses:</i> 40 to 80 mg/day in divided doses 1 to 2 times daily until peak expiratory flow is 70% of predicted or personal best </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Short-course &ldquo;burst&rdquo; (Outpatient):</i> 40 to 60 mg/day in divided doses 1 to 2 times daily for 3 to 10 days; <b>Note:</b> Burst should be continued until symptoms resolve and peak expiratory flow is at least 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GINA 2014:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\"> Infants and Children &lt;12 years: Oral: 1 to 2 mg/kg/day for 3 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maximum daily dose age-dependent:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children &lt;2 years: 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children 2 to 5 years: 30 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children 6 to 11 years: 40 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Oral: 1 mg/kg/day for 5 to 7 days; maximum daily dose 50 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asthma, maintenance therapy (nonacute)</b> (NAEPP 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 year: Oral: 0.25 to 2 mg/kg/day administered as a single dose in the morning or every other day as needed for asthma control; maximum daily dose: 60 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 7.5 to 60 mg daily administered as a single dose in the morning or every other day as needed for asthma control </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Autoimmune hepatitis (monotherapy or in combination with azathioprine):</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day for 2 weeks; maximum daily dose: 60 mg/<b>day</b>; taper upon response over 6 to 8 weeks to a dose of 0.1 to 0.2 mg/kg/day or 2.5 to 5 mg daily; an alternate day schedule to decrease risk of adverse effect has been used; however, a higher incidence of relapse has been observed in some cases and use is not suggested (AASLD [Manns 2010]; Della Corte 2012).  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bell palsy:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;16 years: Oral: 1 mg/kg/day for 1 week, then taper over 1 week; ideally start within the 72 hours of onset of symptoms; maximum daily dose: 60 mg/<b>day</b> (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years: Oral: 60 mg daily for 5 days, followed by a 5-day taper. Treatment should begin within 72 hours of onset of symptoms (OHNS [Baugh 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Congenital adrenal hyperplasia: Note:</b> Individualize dose by monitoring growth, hormone levels, and bone age; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers (AAP 2000; Endocrine Society [Speiser] 2010): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children and Adolescents (actively growing): Not recommended because impedes statural growth more so than shorter-acting systemic glucocorticoid (ie, hydrocortisone) (Endocrine Society [Speiser] 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents (fully grown): Oral:  5 to 7.5 mg daily in divided doses 2 times daily (Endocrine Society [Speiser] 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease:</b> Children and Adolescents: Oral: 1 to 2 mg/kg/day; maximum daily dose: 60 mg/<b>day</b>; continue for 2 to 4 weeks until remission, then gradually taper (Kliegman 2011; Rufo 2012; Sandhu 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis, moderately severe; initial treatment:</b> Limited data available: Children and Adolescents: Oral: Initial: 2 mg/kg/day divided once or twice daily; maximum daily dose: 60 mg/<b>day</b>; continue for 4 weeks then if adequate patient response, begin taper; most recommend an initial 20% reduction in dose with subsequent wean based upon response; use in combination with other immunosuppressants (eg, methotrexate) (CARRA [Huber 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immune thrombocytopenia (ITP):</b> Infants, Children, and Adolescents: Oral: 1 to 2 mg/kg/day; titrate dose according to platelet count; when and if able, a rapid taper is recommended; a maximum duration of therapy of 14 days has been suggested; others have used a higher dose with shorter course of 4 mg/kg/day for 3 to 4 days (Neunert 2011; Provan 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis:</b> Infants &ge; 6 months, Children and Adolescents: Oral: Initial: 1 mg/kg/day administered once daily (maximum daily dose: 60 mg/<b>day</b>); may be used in combination with methylprednisolone pulse therapy; evaluate initial response at 1 to 2 weeks  and then at 1 month of therapy; if patient improves then taper prednisone, if unchanged then continue current prednisone therapy and if worsened then increase dose to 2 mg/kg/day (maximum daily dose: 100 mg/day) . After 1 month, if improvement, begin taper; if condition worsens or unchanged then increase or continue prednisone dose at 2 mg/kg/day (maximum daily dose: 100 mg/day) and/or may add or repeat methylprednisolone pulse therapy. After 3 months of glucocorticoid therapy, if improvement (prednisone dose &lt;50% starting dose), continue taper and reassess monthly; if patient remains unchanged (prednisone dose &gt;50% of starting dose) or worsened, additional therapy should be considered (CARRA [Dewitt 2012]) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis:</b> Children and Adolescents: Oral: Initial therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>With concurrent methylprednisolone pulse therapy:</i> Prednisone: 0.5 to 1.5 mg/kg/day; maximum daily dose: 60 mg/<b>day</b>, taper usually over 6 months to a dose &le;10 mg/day according to clinical response; use in combination with cyclophosphamide or mycophenolate (Bertsias 2012; KDIGO 2012; KDOQI 2013; Mina 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Without concurrent methylprednisolone pulse therapy:</i> Prednisone: 2 mg/kg/day for 6 weeks, maximum daily dose variable: for weeks 1 to 4: maximum daily dose: 80 mg/<b>day</b> and for weeks 5 and 6: 60 mg/<b>day</b>; taper over 6 months; use in combination with cyclophosphamide or mycophenolate (Mina 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignancy (antineoplastic): Note:</b> Used for various types of malignancy and neoplasm; see specific protocols for details concerning dosing in combination regimens. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hodgkin lymphoma (BEACOPP regimen): Children and Adolescents: Oral: 40 mg/m<sup>2</sup>/day in 2 divided doses on days 0 to 13; in combination with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, and procarbazine (Kelly 2002; Kelly 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nephrotic syndrome; steroid-sensitive (SSNS):</b> Children and Adolescents: <b>Note:</b> Obese patients should be dosed based on ideal body weight: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial episode:</i> 2 mg/kg/day or 60 mg/m<sup>2</sup>/day once daily, maximum daily dose: 60 mg/<b>day</b> for 4 to 6 weeks; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m<sup>2</sup>/dose on alternate days as a single dose, maximum dose: 40 mg/dose (Gipson 2009; KDIGO 2012; KDOQI 2013); duration of therapy based on patient response. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Relapse:</i> 2 mg/kg/day or 60 mg/m<sup>2</sup>/day once daily, maximum daily dose: 60 mg/<b>day</b> continue until complete remission for at least 3 days; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/m<sup>2</sup>/dose on alternate days as a single dose, maximum dose: 40 mg/dose, recommended duration of alternate day dosing is variable: may continue for at least 4 weeks then taper. Longer duration of treatment may be necessary in patients who relapse frequently, some patients may require up to 3 months of treatment (Gipson 2009; KDIGO 2012; KDOQI 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance therapy for frequently relapsing SSNS:</i> Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/dose on alternating days; other patients may require doses up to 0.7 mg/kg/dose every other day (KDIGO 2012, KDOQI 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Physiologic replacement:</b> Children and Adolescents: Oral: 2 to 2.5 mg/m<sup>2</sup>/day (Ahmet 2011; Gupta 2008). <b>Note:</b> Hydrocortisone is generally preferred in growing children and adolescents due to its lower growth suppressant effects compared to prednisone (Gupta 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis jirovecii </i> pneumonia (PCP), treatment; HIV-exposed/-positive: </b>\n      <b> Note:</b> Begin as soon as possible after diagnosis and within 72 hours of PCP therapy initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Oral: 1 mg/kg/dose twice daily on days 1 to 5, then 0.5 to 1 mg/kg/dose twice daily on days 6 to 10, then 0.5 mg/kg/dose once daily for days 11 to 21 (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 40 mg twice daily on days 1 to 5, followed by 40 mg once daily on days 6 to 10, followed by 20 mg once daily on days 11 to 21 or until antimicrobial regimen is completed (DHHS [adult] 2014). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis:</b> Children and Adolescents: Oral: 1 to 2 mg/kg/day administered in the morning; maximum daily dose: 60 mg/<b>day</b>; if no response after 7 to 14 days optimal dosing and compliance should be assessed (Kliegman 2011; Rufo 2012; Turner 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing range:</b> Oral: Initial: 5 to 60 mg daily: <b>Note:</b> Dose depends upon condition being treated and response of patient. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prednisone taper (other regimens also available):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 1: 30 mg/day divided as 10 mg before breakfast, 5 mg at lunch, 5 mg at dinner, 10 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 2: 5 mg at breakfast, 5 mg at lunch, 5 mg at dinner, 10 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 3: 5 mg 4 times daily (with meals and at bedtime)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 4: 5 mg 3 times daily (breakfast, lunch, bedtime)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 5: 5 mg 2 times daily (breakfast, bedtime)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 6: 5 mg before breakfast</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute asthma</b> (NAEPP 2007): Oral: 40 to 60 mg per day for 3 to 10 days; administer as single or 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute gout</b> (ACR guidelines [Khanna 2012]): Oral: Initial: &ge;0.5 mg/kg for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antineoplastic:</b> Oral: Usual range: 10 mg daily to 100 mg/m<sup>2</sup>/day (depending on indication). <b>Note:</b> Details concerning dosing in combination regimens should also be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis/polymyositis:</b> Oral: 1 mg/kg daily (range: 0.5 to 1.5 mg/kg/day), often in conjunction with steroid-sparing therapies; depending on response/tolerance, consider slow tapering after 2 to 8 weeks depending on response; taper regimens vary widely, but often involve 5 to 10 mg decrements per week and may require 6 to 12 months to reach a low once-daily or every-other-day dose to prevent disease flare (Briemberg 2003; Hengstman 2009; Iorizzo 2008; Wiendl 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immune thrombocytopenia (ITP)</b> (American Society of Hematology 1997): Oral: 1 to 2 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis, induction</b> (Hahn 2012): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Class III-IV lupus nephritis: 0.5 to 1 mg/kg/day (after glucocorticoid pulse) tapered after a few weeks to lowest effective dose, in combination with an immunosuppressive agent</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Class V lupus nephritis: 0.5 mg/kg/day for 6 months in combination mycophenolate mofetil; if not improved after 6 months, use 0.5 to 1 mg/kg/day (after a glucocorticoid pulse) for an additional 6 months in combination with cyclophosphamide</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis</b> (American College of Rheumatology 2002): Oral: &le;10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. Prednisone is inactive and must be metabolized by the liver to prednisolone. This conversion may be impaired in patients with liver disease; however, prednisolone levels are observed to be higher in patients with severe liver failure than in normal patients. Therefore, compensation for the inadequate conversion of prednisone to prednisolone occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213075\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PredniSONE Intensol: 5 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (5 mL [DSC], 120 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Deltasone: 20 mg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg, 10 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rayos: 1 mg, 2 mg, 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (21 ea, 48 ea); 5 mg (21 ea, 48 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213060\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055064\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer after meals or with food or milk to decrease GI upset. Delayed release tablet (Rayos) should be swallowed whole; do not crush, divide, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45503517\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 25&#730;C (77&#730;F); excursions permitted to 15&#730;C to 30&#730;C (59&#730;F to 86&#730;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution, concentrate: Discard opened bottle after 90 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055063\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of allergic, hematologic, dermatologic, gastrointestinal, inflammatory, ophthalmic, neoplastic, rheumatic, autoimmune, nervous system, renal, and respiratory origin (Immediate release: FDA approved in infants, children, adolescents, and adults; delayed release [Rayos]: FDA approved in pediatric patients [age not specified] and adults); primary or secondary adrenocorticoid deficiency (not first-line) (Immediate release: FDA approved in infants, children, adolescents, and adults; delayed release [Rayos]: FDA approved in pediatric patients [age not specified] and adults); solid organ rejection (acute/chronic) (delayed release [Rayos]: FDA approved in pediatric patients [age not specified] and adults); has also been used for treatment of  Bell palsy, autoimmune hepatitis, and <i>Pneumocystis jirovecii</i> pneumonia  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213155\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">PredniSONE may be confused with methylPREDNISolone, Pramosone, prazosin, prednisoLONE, PriLOSEC, primidone, promethazine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213151\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure (in susceptible patients), hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Emotional lability, headache, increased intracranial pressure (with papilledema), myasthenia, psychiatric disturbance (including euphoria, insomnia, mood swings, personality changes, severe depression), seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, facial erythema, skin atrophy, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Cushing&rsquo;s syndrome, decreased serum potassium, diabetes mellitus, fluid retention, growth suppression (children), hypokalemic alkalosis, hypothyroidism (enhanced), menstrual disease, negative nitrogen balance (due to protein catabolism), sodium retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, carbohydrate intolerance, pancreatitis, peptic ulcer (with possible perforation and hemorrhage), ulcerative esophagitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise, Kaposi&rsquo;s sarcoma, petechia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy, aseptic necrosis of bones (femoral and humeral heads), osteoporosis, pathological fracture (long bones), rupture of tendon (particularly Achilles tendon), steroid myopathy, vertebral compression fracture</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, subcapsular posterior cataract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Wound healing impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Venous thrombosis (Johannesdottir 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to prednisone or any component of the formulation; administration of live or live attenuated vaccines with immunosuppressive doses of prednisone; systemic fungal infections</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213064\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used to treat viral hepatitis or cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropic climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with Strongyloides infections; hyperinfection, dissemination and fatalities have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression or frank psychotic manifestations. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF and/or hypertension; long-term use has been associated with electrolyte disturbances, fluid retention, and hypertension. Use with caution in patients with a recent history of myocardial infarction (MI); left ventricular free wall rupture has been reported after the use of corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis [nonspecific]) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; effects may be enhanced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Use with caution in patients with or who are at risk for osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly with the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May affect growth velocity; growth and development should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26075621\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard 2007). Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose dependent and produce a greater IOP in children &lt;6 years than older children treated with ophthalmic dexamethasone (Lam 2005). Corticosteroids have been associated with myocardial rupture; hypertrophic cardiomyopathy has been reported in premature neonates. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213138\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213069\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12725&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Corticosteroids (Systemic). Management: No dose adjustment is needed for single 40 mg aprepitant doses. For other regimens, reduce oral dexamethasone or methylprednisolone doses by 50%, and IV methylprednisolone doses by 25%. Antiemetic regimens containing dexamethasone reflect this adjustment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel.  Management: Avoid use of corticosteroids as premedication before axicabtagene ciloleucel. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: May diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids (Systemic).  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tesamorelin: May decrease serum concentrations of the active metabolite(s) of PredniSONE.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Corticosteroids (Systemic) may diminish the therapeutic effect of Tisagenlecleucel.  Management: Avoid use of corticosteroids as premedication or at any time during treatment with tisagenlecleucel, except in the case of life-threatening emergency (such as resistant cytokine release syndrome).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21283998\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C/D (product specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213086\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Prednisone and its metabolite, prednisolone, cross the human placenta. In the mother, prednisone is converted to the active metabolite prednisolone by the liver. Prior to reaching the fetus, prednisolone is converted by placental enzymes back to prednisone. As a result, the level of prednisone remaining in the maternal serum and reaching the fetus are similar; however, the amount of prednisolone reaching the fetus is ~8 to 10 times lower than the maternal serum concentration (healthy women at term) (Beitins 1972).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When systemic corticosteroids are needed in pregnancy for rheumatic disorders, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (G&ouml;testam Skorpen 2016; Makol 2011; &Oslash;stensen 2009).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For dermatologic disorders in pregnant women, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Bae 2012; Leachman 2006). Prednisone is preferred by some guidelines when an oral corticosteroid is needed because placental enzymes limit passage to the embryo (Murase 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women with poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used medications. Uncontrolled asthma is associated with an increased risk of perinatal mortality, preeclampsia, preterm birth, and low birth weight infants. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids, including prednisone, should be used to control acute exacerbations or treat severe persistent asthma (ACOG 2008; GINA 2016; Namazy 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prednisone may be used to treat lupus nephritis in pregnant women who have active nephritis or substantial extrarenal disease activity (Hahn 2012). Prednisone is recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated immune thrombocytopenia (ACOG 2016). Prednisone may be used (alternative agent) to treat primary adrenal insufficiency (PAI) in pregnant women. Pregnant women with PAI should be monitored at least once each trimester (Bornstein 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055059\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); Hgb, occult blood loss. Monitor IOP with therapy &gt;6 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213063\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system; suppresses adrenal function at high doses. Antitumor effects may be related to inhibition of glucose transport, phosphorylation, or induction of cell death in immature lymphocytes. Antiemetic effects are thought to occur due to blockade of cerebral innervation of the emetic center via inhibition of prostaglandin synthesis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213081\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: 50% to 90% (may be altered in hepatic failure, chronic renal failure, inflammatory bowel disease, hyperthyroidism, and in the elderly) (Frey 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding (concentration dependent): &lt;50% (Frey 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to metabolite prednisolone (active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: Immediate-release tablet: 2 hours; Delayed-release tablet: 6 to 6.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as conjugates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213085\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (PredniSONE Intensol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $156.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (PredniSONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (120 mL): $96.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (PredniSONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG (21) (21): $16.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG (48) (48): $27.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10MG (21) (21): $29.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10MG (48) (48): $41.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Rayos Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $3,012.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (30): $3,012.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $3,012.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Deltasone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (20): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (PredniSONE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $25.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $16.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $22.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $24.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $25.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $40.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213089\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfacort (UY);</li>\n      <li>Apo-Prednisone (NZ);</li>\n      <li>Cortancyl (FR, LB);</li>\n      <li>Cortiol (PT);</li>\n      <li>Cortiprex (CL, PE, PY);</li>\n      <li>Cutason (DE);</li>\n      <li>Dacortin (CH, ES);</li>\n      <li>Decortin (DE, HR);</li>\n      <li>Decortisyl (IE);</li>\n      <li>Dehydrocortison (BG);</li>\n      <li>Delcortin (DK);</li>\n      <li>Deltacortene (IT);</li>\n      <li>Deltasone (HK);</li>\n      <li>Deltison (SE);</li>\n      <li>Ednapron (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Encorton (PL);</li>\n      <li>Hostacortin (ID);</li>\n      <li>Lexacort (ID);</li>\n      <li>Lodotra (AU, ES, GB, HU, IL, KR, LU, RO, SG, SK, TR);</li>\n      <li>Me-Korti (FI);</li>\n      <li>Meticorten (AR, BR, CL, CO, CR, DO, GT, HN, MX, NI, PA, PE, PT, SV, VE);</li>\n      <li>Metilpres (AR);</li>\n      <li>Nisona (PE);</li>\n      <li>Nizon (HR);</li>\n      <li>Norapred (MX);</li>\n      <li>Nurison (NL);</li>\n      <li>Orapred (PE);</li>\n      <li>Panafcort (AU, ZA, ZW);</li>\n      <li>Parmenison (AT);</li>\n      <li>Pehacort (ID);</li>\n      <li>Predicor (LB);</li>\n      <li>Prednicort (BE, LU, PY);</li>\n      <li>Prednidib (MX);</li>\n      <li>Predniment (NL);</li>\n      <li>Prednimut (NL);</li>\n      <li>Prednison (FI, NO);</li>\n      <li>Prednison Galepharm (CH);</li>\n      <li>Prednison Streuli (CH);</li>\n      <li>Prednison &rdquo;Dak&rdquo; (DK);</li>\n      <li>Prednisone (CY);</li>\n      <li>Predone (QA, SA);</li>\n      <li>Predoral (PH);</li>\n      <li>Predsone (PH);</li>\n      <li>Presacor (EC);</li>\n      <li>Prolix 20 (PH);</li>\n      <li>Pulmison (ZA);</li>\n      <li>Qualisone (PH);</li>\n      <li>Rectodelt (HU);</li>\n      <li>Sone (AU);</li>\n      <li>Systocor (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2011;(7):13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/21867553 /pubmed\" target=\"_blank\" id=\"21867553 \">21867553 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics. Technical report congenital adrenal hyperplasia. <i>Pediatrics</i>. 2000;106(6):1511-1518.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/11099616 /pubmed\" target=\"_blank\" id=\"11099616 \">11099616 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Statement of endorsement-congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Pediatrics. 2010;126(5):1051. Available at http://pediatrics.aappublications.org/cgi/content/extract/126/5/1051. Accessed May 10, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG), ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. <i>Obstet Gynecol</i>. 2008;111(2 Pt 1):457-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. <i>Arthritis Rheum</i>. 2002;46(2):328-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/11840435/pubmed\" target=\"_blank\" id=\"11840435\">11840435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al, &quot;Review of Treatment Options For Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation,&quot; <i>J Am Acad Dermatol</i>, 2012, 67(3):459-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahn RS (Chair), Burch HB, Cooper DS, et al, &ldquo;Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,&rdquo; <i>Thyroid</i>, 2011, 21(6):593-646.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/ 21510801/pubmed\" target=\"_blank\" id=\" 21510801\"> 21510801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. <i>Otolaryngol Head Neck Surg</i>. 2013;149(3 suppl):s1-s27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/24189771/pubmed\" target=\"_blank\" id=\"24189771\">24189771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beitins IZ, Bayard F, Ances IG, et al, &ldquo;The Transplacental Passage of Prednisone and Prednisolone in Pregnancy Near Term,&rdquo; <i>J Pediatr</i>, 1972, 81(5):936-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/5086721/pubmed\" target=\"_blank\" id=\"5086721\">5086721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlin Jr CM, Kaiser DG, Demers L. Excretion of prednisone and prednisolone in human milk. <i>Pharmacologist</i>. 1979;21:264.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.<i> Ann Rheum Dis</i>. 2012;71(11):1771-1782.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22851469 /pubmed\" target=\"_blank\" id=\"22851469 \">22851469 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/26760044/pubmed\" target=\"_blank\" id=\"26760044\">26760044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briemberg HR, Amato AA. Dermatomyositis and polymyositis. <i>Curr Treat Options Neurol</i>. 2003;5(5):349-356.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/12895397 /pubmed\" target=\"_blank\" id=\"12895397 \">12895397 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng A. Emergency treatment of anaphylaxis in infants and children.<i> Paediatr Child Health</i>. 2011;16(1):35-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22211074 /pubmed\" target=\"_blank\" id=\"22211074 \">22211074 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Della Corte C, Sartorelli MR, Sindoni CD, et al. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. <i>Eur J Gastroenterol Hepatol</i>. 2012;24(7):739-746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22495399 /pubmed\" target=\"_blank\" id=\"22495399 \">22495399 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22290637 /pubmed\" target=\"_blank\" id=\"22290637 \">22290637 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel. <i>Ann Intern Med</i>. 1997;126(4):319-326.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/9036806 /pubmed\" target=\"_blank\" id=\"9036806 \">9036806 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19651590 /pubmed\" target=\"_blank\" id=\"19651590 \">19651590 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2014. Available at www.ginaasthma.org</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&ouml;testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Ann Rheum Dis</i>. 2016;75(5):795-810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/26888948/pubmed\" target=\"_blank\" id=\"26888948\">26888948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta P, Bhatia V. Corticosteroid physiology and principles of therapy. <i>Indian J Pediatr</i>. 2008;75(10):1039-1044.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19023528 /pubmed\" target=\"_blank\" id=\"19023528 \">19023528 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. <i>Expert Opin Pharmacother</i>. 2009;10(7):1183-1190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19405792 /pubmed\" target=\"_blank\" id=\"19405792 \">19405792 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care Res (Hoboken)</i>. 2010;62(2):219-225.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/20191521 /pubmed\" target=\"_blank\" id=\"20191521 \">20191521 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. <i>J Am Acad Dermatol</i>. 2008;59(1):99-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/18423790 /pubmed\" target=\"_blank\" id=\"18423790 \">18423790 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &ldquo;Prospective Follow-up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&rdquo; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johannesdottir SA, Horv&aacute;th-Puh&oacute; E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. <i>JAMA Intern Med</i>. 2013;173(9):743-752.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/23546607 /pubmed\" target=\"_blank\" id=\"23546607 \">23546607 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz FH and Duncan BR, &quot;Letter: Entry of Prednisone Into Human Milk,&quot;<i> N Engl J Med</i>, 1975, 293(22):1154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/1186783/pubmed\" target=\"_blank\" id=\"1186783\">1186783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDIGO. Clinical Practice Guideline for Glomerulonephritis. <i>Kidney International Supplements</i>. June 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDIGO. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. <i>Am J Kidney Dis</i>. 2013;62(3):403-441.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. <i>Ann Oncol</i>. 2002;13(Suppl 1):107-111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/12078889 /pubmed\" target=\"_blank\" id=\"12078889 \">12078889 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Blood</i>. 2011;117(9):2596-2603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/21079154 /pubmed\" target=\"_blank\" id=\"21079154 \">21079154 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1447-1461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/23024029 /pubmed\" target=\"_blank\" id=\"23024029 \">23024029 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam DS, Fan DS, Ng JS, et al, &quot;Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,&quot; <i>Clin Experiment Ophthalmol</i>, 2005, 33(3):252-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/15932528/pubmed\" target=\"_blank\" id=\"15932528\">15932528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonard MB, &quot;Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,&quot; <i>Pediatrics</i>, 2007, 119 Suppl 2:S166-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/17332238/pubmed\" target=\"_blank\" id=\"17332238\">17332238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i>. 2010;51(6):2193-2213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/20513004 /pubmed\" target=\"_blank\" id=\"20513004 \">20513004 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(3):375-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22162255 /pubmed\" target=\"_blank\" id=\"22162255 \">22162255 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/27012010/pubmed\" target=\"_blank\" id=\"27012010\">27012010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/21325604 /pubmed\" target=\"_blank\" id=\"21325604 \">21325604 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ost L, Wettrell G, Bjorkhem I, et al, &quot;Prednisolone Excretion in Human Milk,&quot; <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/3998938/pubmed\" target=\"_blank\" id=\"3998938\">3998938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &ldquo;Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-analysis of Epidemiological Studies,&rdquo; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/20047480 /pubmed\" target=\"_blank\" id=\"20047480 \">20047480 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19846889 /pubmed\" target=\"_blank\" id=\"19846889 \">19846889 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rayos (prednisone) [prescribing information]. Deerfield, IL; Horizon Pharma USA, Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22516861 /pubmed\" target=\"_blank\" id=\"22516861 \">22516861 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sagraves R, Kaiser D, and Sharpe GL, &ldquo;Prednisone and Prednisolone Concentrations in the Milk of a Lactating Mother,&rdquo; <i>Drug Intell Clin Pharm</i>, 1981, 15:484.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom.<i> J Pediatr Gastroenterol Nutr</i>. 2010;(50 Suppl 1):S1-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/20081543 /pubmed\" target=\"_blank\" id=\"20081543 \">20081543 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.<i> J Clin Endocrinol Metab</i>. 2010;95(9):4133-4160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/20823466 /pubmed\" target=\"_blank\" id=\"20823466 \">20823466 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(3):340-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/22773060 /pubmed\" target=\"_blank\" id=\"22773060 \">22773060 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. <i>Neurotherapeutics</i>. 2008;5(4):548-557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/19019306 /pubmed\" target=\"_blank\" id=\"19019306 \">19019306 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prednisone-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12725 Version 238.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F213098\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F213099\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055060\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055053\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F213075\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F213060\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055064\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45503517\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055063\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F213155\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F213151\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F213082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F213064\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26075621\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F213138\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F213069\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F21283998\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F213086\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055059\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F213063\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F213081\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F213085\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F213089\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12725|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">Prednisone: Drug information</a></li><li><a href=\"topic.htm?path=prednisone-patient-drug-information\" class=\"drug drug_patient\">Prednisone: Patient drug information</a></li></ul></div></div>","javascript":null}